Cargando…

Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence

BACKGROUND: Shu Gan Jie Yu (SGJY) capsule has a good effect on relieving depressive symptoms in China. However, the mechanism of action is still unclear. Therefore, systemic pharmacology and molecular docking approaches were used to clarify its corresponding antidepressant mechanisms. METHODS: Tradi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Taiping, Qiu, Tian, Zeng, Yanyan, Kang, Bing, Tang, Xianglong, Yang, Ning, Xiao, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423969/
https://www.ncbi.nlm.nih.gov/pubmed/36045654
http://dx.doi.org/10.1155/2022/3321099
_version_ 1784778134572236800
author Li, Taiping
Qiu, Tian
Zeng, Yanyan
Kang, Bing
Tang, Xianglong
Yang, Ning
Xiao, Hong
author_facet Li, Taiping
Qiu, Tian
Zeng, Yanyan
Kang, Bing
Tang, Xianglong
Yang, Ning
Xiao, Hong
author_sort Li, Taiping
collection PubMed
description BACKGROUND: Shu Gan Jie Yu (SGJY) capsule has a good effect on relieving depressive symptoms in China. However, the mechanism of action is still unclear. Therefore, systemic pharmacology and molecular docking approaches were used to clarify its corresponding antidepressant mechanisms. METHODS: Traditional Chinese Medicine Database and Analysis Platform (TCMSP), the Encyclopedia of Traditional Chinese Medicine (ETCM), and Swiss Target Prediction servers were used to screen and predict the bioactive components of the SGJY capsule and their antidepressive targets. Mild to moderate depression (MMD) related genes were obtained from GeneCards and DisGeNET databases. A network of bioactive components-therapeutic targets of the SGJY capsule was established by STRING 11.5 and Cytoscape 3.9.0 software. Gene function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed by utilizing Database for Annotation, Visualization, and Integrated Discovery (DAVID) platform. Active components were taken to dock with the hypothetical proteins by iGEMDOCK and SwissDock, and the docking details were visually displayed by UCSF Chimera software. Then, the related research literature of the SGJY capsule was reviewed, summarized, sorted, and analyzed, including experimental evidence and clinical experience. RESULTS: Seven active components and 45 intersection targets were included in the study. PPI network had genuinely uncovered the potential therapeutic targets, such as AKT1, HSP90AA1, ESR1, EGFR, and PTGS2. KEGG pathway analysis showed that the mechanism of the SGJY capsule on MMD was mainly involved in the PI3K-Akt signaling pathway. CONCLUSIONS: In this study, we have successfully predicted the biochemically active constituents, potential therapeutic targets, and comprehensively predicted the related drug-gene interaction of the SGJY capsule for treating MMD and provided a basis for subsequent experiments.
format Online
Article
Text
id pubmed-9423969
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94239692022-08-30 Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence Li, Taiping Qiu, Tian Zeng, Yanyan Kang, Bing Tang, Xianglong Yang, Ning Xiao, Hong Evid Based Complement Alternat Med Research Article BACKGROUND: Shu Gan Jie Yu (SGJY) capsule has a good effect on relieving depressive symptoms in China. However, the mechanism of action is still unclear. Therefore, systemic pharmacology and molecular docking approaches were used to clarify its corresponding antidepressant mechanisms. METHODS: Traditional Chinese Medicine Database and Analysis Platform (TCMSP), the Encyclopedia of Traditional Chinese Medicine (ETCM), and Swiss Target Prediction servers were used to screen and predict the bioactive components of the SGJY capsule and their antidepressive targets. Mild to moderate depression (MMD) related genes were obtained from GeneCards and DisGeNET databases. A network of bioactive components-therapeutic targets of the SGJY capsule was established by STRING 11.5 and Cytoscape 3.9.0 software. Gene function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed by utilizing Database for Annotation, Visualization, and Integrated Discovery (DAVID) platform. Active components were taken to dock with the hypothetical proteins by iGEMDOCK and SwissDock, and the docking details were visually displayed by UCSF Chimera software. Then, the related research literature of the SGJY capsule was reviewed, summarized, sorted, and analyzed, including experimental evidence and clinical experience. RESULTS: Seven active components and 45 intersection targets were included in the study. PPI network had genuinely uncovered the potential therapeutic targets, such as AKT1, HSP90AA1, ESR1, EGFR, and PTGS2. KEGG pathway analysis showed that the mechanism of the SGJY capsule on MMD was mainly involved in the PI3K-Akt signaling pathway. CONCLUSIONS: In this study, we have successfully predicted the biochemically active constituents, potential therapeutic targets, and comprehensively predicted the related drug-gene interaction of the SGJY capsule for treating MMD and provided a basis for subsequent experiments. Hindawi 2022-08-22 /pmc/articles/PMC9423969/ /pubmed/36045654 http://dx.doi.org/10.1155/2022/3321099 Text en Copyright © 2022 Taiping Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Taiping
Qiu, Tian
Zeng, Yanyan
Kang, Bing
Tang, Xianglong
Yang, Ning
Xiao, Hong
Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence
title Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence
title_full Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence
title_fullStr Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence
title_full_unstemmed Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence
title_short Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence
title_sort potential mechanisms of shu gan jie yu capsule in the treatment of mild to moderate depression based on systemic pharmacology and current evidence
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423969/
https://www.ncbi.nlm.nih.gov/pubmed/36045654
http://dx.doi.org/10.1155/2022/3321099
work_keys_str_mv AT litaiping potentialmechanismsofshuganjieyucapsuleinthetreatmentofmildtomoderatedepressionbasedonsystemicpharmacologyandcurrentevidence
AT qiutian potentialmechanismsofshuganjieyucapsuleinthetreatmentofmildtomoderatedepressionbasedonsystemicpharmacologyandcurrentevidence
AT zengyanyan potentialmechanismsofshuganjieyucapsuleinthetreatmentofmildtomoderatedepressionbasedonsystemicpharmacologyandcurrentevidence
AT kangbing potentialmechanismsofshuganjieyucapsuleinthetreatmentofmildtomoderatedepressionbasedonsystemicpharmacologyandcurrentevidence
AT tangxianglong potentialmechanismsofshuganjieyucapsuleinthetreatmentofmildtomoderatedepressionbasedonsystemicpharmacologyandcurrentevidence
AT yangning potentialmechanismsofshuganjieyucapsuleinthetreatmentofmildtomoderatedepressionbasedonsystemicpharmacologyandcurrentevidence
AT xiaohong potentialmechanismsofshuganjieyucapsuleinthetreatmentofmildtomoderatedepressionbasedonsystemicpharmacologyandcurrentevidence